Valuation: China Shineway Pharmaceutical Group Limited

Market Cap 5.45B 6.4B 817M 744M 686M 624M 1.17B 75.64B 1.23B 8.34B 3.32B 41.32B 3.07B 3B 130B P/E 2026 *
6.97x
P/E 2027 * 6.46x
Enterprise Value 5.45B 6.4B 817M 744M 686M 624M 1.17B 75.64B 1.23B 8.34B 3.32B 41.32B 3.07B 3B 130B EV / Sales 2026 *
2.18x
EV / Sales 2027 * 2.11x
Free-Float
33.69%
Yield 2026 *
-
Yield 2027 * -
06/11 China Shineway Pharmaceutical Group Limited Reports Unaudited Group Turnover Results for the Nine Months Ended 30 September 2026 CI
30/10 China Shineway Pharmaceutical Group Limited Announces Appointment of Kang Limin as Executive Director, Effective November 1, 2026 CI
29/09 China Shineway Pharmaceutical Group Limited Announces Board and Committee Changes, Effective 1 October 2026 CI
18/09 China Shineway Pharmaceutical Group Limited Declares Special Interim Dividend in Respect of the Fiscal Year Ending 31 December 2026, Payable on 15 October 2026 CI
27/08 China Shineway Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
27/08 China Shineway Pharmaceutical Group Limited Declares Second Interim Dividend in Respect of the Fiscal Year Ended December 31, 2026, Payable on 25 September 2026 CI
07/05 China Shineway Pharmaceutical's Turnover Slides 18% in Q1 MT
07/05 China Shineway Pharmaceutical posts Q1 turnover of RMB624 mln RE
07/05 China Shineway Pharmaceutical Group Limited Reports Unaudited Turnover Results for the First Quarter Ended 31 March 2026 CI
28/03 China Shineway Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
27/03 China Shineway Pharmaceutical declares 2026 first interim dividend RMB43 cents per share RE
27/03 China Shineway Pharma's Profit Climbs 13% in 2025 MT
27/03 China Shineway Pharmaceutical Group Limited Approves Dividend for First Interim Dividend in Respect of the Fiscal Year Ending 31 December 2026, Payable on May 19, 2026 CI
1 day+4.44%
1 week+11.15%
Current month+12.92%
1 month+13.91%
3 months+6.00%
6 months-1.22%
Current year-1.45%
1 week 7.56
Extreme 7.56
8.5
1 month 7.18
Extreme 7.185
8.5
Current year 7.12
Extreme 7.12
10.47
1 year 7.12
Extreme 7.12
10.47
3 years 6.61
Extreme 6.61
10.76
5 years 4.63
Extreme 4.63
10.76
10 years 4.6
Extreme 4.6
18.54
Manager TitleAgeSince
Investor Relations Contact 60 -
Sales & Marketing 46 01/12/2019
Comptroller/Controller/Auditor 53 01/02/2011
Director TitleAgeSince
Chairman 70 14/08/2002
Director/Board Member 58 -
Director/Board Member 50 01/10/2020
Date Insider Type Main position Quantity % Market Cap. Importance
31/10/22 Other

Director

280,000 0.0339%
Change 5-day change 1-year change 3-year change Capi.($)
+4.44%+11.15%-2.02%+22.47% 781M
+0.07%-6.36%+29.56%+126.19% 1,204B
+1.76%-4.89%+33.83%+81.29% 643B
+1.75%-2.22%+25.72%+108.57% 501B
-0.60%-1.95%+27.26%+67.32% 378B
+1.33%-8.83%+41.86%+31.20% 327B
+0.41%-4.70%+27.23%+51.59% 285B
+0.81%-4.08%-1.74%+32.71% 270B
+0.55%-5.67%+30.70%+65.54% 237B
+0.84%+0.10%+34.60%+121.37% 207B
Average +1.12%-3.32%+24.70%+70.83% 405B
Weighted average by Cap. +0.71%-4.71%+28.61%+88.43%

Financials

2026 *2027 *
Net sales 2.5B 2.94B 375M 342M 315M 286M 537M 34.74B 565M 3.83B 1.52B 18.98B 1.41B 1.38B 59.56B 2.59B 3.04B 387M 353M 325M 296M 555M 35.87B 583M 3.96B 1.57B 19.59B 1.45B 1.42B 61.49B
Net income 821M 964M 123M 112M 103M 93.92M 176M 11.39B 185M 1.26B 499M 6.22B 462M 452M 19.53B 885M 1.04B 133M 121M 111M 101M 190M 12.28B 200M 1.35B 538M 6.71B 498M 487M 21.06B
Net Debt - -
Projected Income Statement - Annual - China Shineway Pharmaceutical Group Limited
Logo China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Employees
2,656
Date Price Change Volume
20/11/26 HKD 8.475 +4.44% 3,490,000
19/11/26 HKD 8.115 +2.53% 1,407,000
18/11/26 HKD 7.915 +1.47% 1,175,000
17/11/26 HKD 7.800 +0.39% 720,000
16/11/26 HKD 7.770 +2.30% 1,937,000
Trader
Investor
-
Global
-
Quality
ESG MSCI
BBB
MarketScreener Ratings - China Shineway Pharmaceutical Group Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
7.219CNY
Average target price
7.922CNY
Spread / Average Target
+9.75%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - China Shineway Pharmaceutical Group Limited
  1. Stock Market
  2. Stocks
  3. 2877 Stock